Working… Menu

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03345095
Recruitment Status : Recruiting
First Posted : November 17, 2017
Last Update Posted : June 17, 2019
Canadian Cancer Trials Group
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary:
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with TMZ/RT -->TMZ in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma. In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.

Condition or disease Intervention/treatment Phase
Newly Diagnosed Glioblastoma Drug: Marizomib Drug: Temozolomide Radiation: radiotherapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 750 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Actual Study Start Date : July 26, 2018
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Experimental Arm
Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
Drug: Marizomib
Intravenous administration of Marizomib
Other Name: MRZ

Drug: Temozolomide
Oral Administration of Temozolomide
Other Name: TMZ

Radiation: radiotherapy
60 Gy in 30 fractions over 6 weeks
Other Name: RT

Active Comparator: Standard Arm
Radiotherapy + Temozolomide followed by adjuvant Temozolomide
Drug: Temozolomide
Oral Administration of Temozolomide
Other Name: TMZ

Radiation: radiotherapy
60 Gy in 30 fractions over 6 weeks
Other Name: RT

Primary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: From the date of randomization up to the date of death, assessed up to 49 months ]

Secondary Outcome Measures :
  1. Progression Free Survival (PFS) [ Time Frame: From the date of randomization until the date of first objective progression or the date of patient's death whichever occurs first, assessed up to 49 months ]
  2. Health-related Quality of life (HRQol) [ Time Frame: From randomization until progression, assessed up to 49 months ]
    HRQoL will be assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3.

  3. Mini Mental State Examination (MMSE) [ Time Frame: From the date of randomization until end of treatment, assessed up to 49 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed newly diagnosed glioblastoma (WHO grade IV)
  • Tumor resection (gross total or partial), or biopsy only
  • Availability of FFPE tumor block or 24 unstained slides for MGMT analysis
  • Patient must be eligible for standard TMZ/RT + TMZ
  • Karnofsky performance score (KPS) ≥ 70
  • Recovered from effects of surgery, postoperative infection and other complications of surgery (if any)
  • The patient is at least 18 years of age on day of signing informed consent
  • Stable or decreasing dose of steroids for at least 1 week prior to inclusion
  • The patient has a life expectancy of at least 3 months
  • Patient has undergone a brain MRI within 14 days of randomization but after intervention (resection or biopsy)
  • The patient shows adequate organ functions as assessed by the specified laboratory values within 2 weeks prior to randomization defined as adequate bone marrow, renal and hepatic function within the following ranges:

    • WBC ≥ 3×10*9/L
    • ANC ≥ 1.5×10*9/L
    • Platelet count of ≥ 100×10*9/L independent of transfusion
    • Hemoglobin ≥ 10 g/dl
    • Total Bilirubin ≤ 1.5 ULN
    • ALT, AST, alkaline phosphatase (ALP) ≤ 2.5 × ULN
    • Serum creatinine < 1.5 x ULN or creatinine clearance (CrCl) > 30 mL/min(using the Cockcroft-Gault formula)
  • Women of child bearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to the first dose of study treatment.
  • Patients of childbearing / reproductive potential must agree to use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1 percent per year) when used consistently and correctly. Patients must also agree not to donate sperm during the study and for 6 months after receiving the last dose of study treatment.
  • Women who are breast feeding must agree to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
  • Ability to take oral medication
  • Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
  • Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03345095

Layout table for location contacts
Contact: EORTC +3227741611

  Hide Study Locations
Layout table for location information
Kepler University Hospital Recruiting
Linz, Austria, 4020
Contact: Josef Pichler         
Medical University Vienna - General Hospital AKH Recruiting
Vienna, Austria, 1090
Principal Investigator: Matthias Preusser, Dr         
Onze Lieve Vrouw Ziekenhuis Recruiting
Aalst, Belgium, 9300
Principal Investigator: Luc Verbeke, Dr         
GasthuisZusters Antwerpen - Sint-Augustinus Recruiting
Antwerpen, Belgium
Principal Investigator: Paul Meijnders, Dr         
Hopitaux Universitaires Bordet-Erasme - Hopital Universitaire Erasme Recruiting
Bruxelles, Belgium, 1070
Principal Investigator: Florence Lefranc, Dr         
Cliniques Universitaires Saint-Luc Recruiting
Bruxelles, Belgium
Principal Investigator: Nicolas Whenham, Dr         
Grand Hopital de Charleroi - Grand Hôpital de Charleroi - Site Notre Dame Recruiting
Charleroi, Belgium
Principal Investigator: Vincent Verschaeve, Dr         
Universitair Ziekenhuis Gent Recruiting
Gent, Belgium, 9000
Principal Investigator: Tom Boterberg, Dr         
C.H.U. Sart-Tilman Recruiting
Liège, Belgium
Principal Investigator: Pierre Freres, Dr         
Canada, Ontario
London Regional Cancer Center Recruiting
London, Ontario, Canada, N6A 4L6
Principal Investigator: Erin Morgan         
Windsor Regional Cancer Centre Recruiting
Windsor, Ontario, Canada
Principal Investigator: Kay Amin, Dr         
BCCA - Abbotsford Centre Recruiting
Abbotsford, Canada
Principal Investigator: Muhammad Zulfiqar, Dr         
Hamilton Health Sciences, Juravinski Cancer Centre Recruiting
Hamilton, Canada
Principal Investigator: Alejandro Torres-Trejo, Dr         
Kingston Health Sciences Centre Recruiting
Kingston, Canada, CA K7L 2V7
Principal Investigator: Hammad Nazik         
CHUM - Centre Hospitalier de l'Université de Montreal - Hopital Notre-Dame Recruiting
Montréal, Canada
Principal Investigator: Laura Masucci Giuseppina         
Hopital Du Sacre-Coeur De Montreal Recruiting
Montréal, Canada
Principal Investigator: Guylaine Gaudet, Dr         
CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) Recruiting
Québec, Canada
Principal Investigator: Andre Blais         
Allan Blair Cancer Centre Recruiting
Regina, Canada
Principal Investigator: Ibrahim Chalchal Haji         
Sault Area Hospital Recruiting
Sault Ste. Marie, Canada
Principal Investigator: Silvana Spadafora, Dr         
Regional Cancer Program of Hopital Reg. de Sudbury Reg. Hospital Recruiting
Sudbury, Canada
Principal Investigator: Lacey Pitre, Dr         
Odette Cancer Centre - Sunnybrook Health Sciences Centre Recruiting
Toronto, Canada
Principal Investigator: James Perry         
University Health Network - Oci / Princess Margaret Hospital Recruiting
Toronto, Canada
Principal Investigator: Mason Warren         
Centre hospitalier regional de Trois-Rivieres Recruiting
Trois-Rivières, Canada
Principal Investigator: Anouk Tremblay, Dr         
Cancercare Manitoba Recruiting
Winnipeg, Canada
Principal Investigator: Marshall W. Pitz, Dr         
Aarhus University Hospitals - Aarhus University Hospital (440) Recruiting
Aarhus, Denmark, 8000
Principal Investigator: Slavka Lukacova, Dr         
CHU de Lyon - CHU Lyon - Hopital neurologique Pierre Wertheimer Recruiting
Bron, France, 69677
Principal Investigator: Francois Ducray, Dr.         
CHRU de Lille Recruiting
Lille, France
Principal Investigator: Emilie Le Rhun, Dr         
Institut de Cancerologie de l'Ouest Recruiting
Nantes, France
Principal Investigator: Jean-Sebastien Frenel         
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere Recruiting
Paris, France
Principal Investigator: Ahmed Idbaih, Dr         
Gustave Roussy Recruiting
Villejuif, France
Principal Investigator: Guillaume Louvel, Dr         
Universitaetsklinik Erlangen-Neurologische Klinik (3031) Recruiting
Erlangen, Germany, 91054
Contact: Martin Uhl, MD         
Principal Investigator: Martin Uhl, MD         
UniversitaetsKlinikum Heidelberg - Head Hospital Recruiting
Heidelberg, Germany, 69120
Principal Investigator: Antje Wick         
Universitaetsklinikum Leipzig-Klinik für Strahlentherapie und Radioonkologie Recruiting
Leipzig, Germany, 04103
Contact: , Dr         
Principal Investigator: Clemens Seidel, Dr         
Johannes Gutenberg Universitaetskliniken - Mainz University Medical Center Recruiting
Mainz, Germany, 55131
Principal Investigator: Florian Ringel, Dr         
UniversitaetsMedizin Mannheim Recruiting
Mannheim, Germany, 68167
Principal Investigator: Iris Mildenberger, Dr         
Technische Universitaet Muenchen - Klinikum Rechts Der Isar Recruiting
Muenchen, Germany, 81675
Principal Investigator: Jens Gempt, Dr.         
Universitaetskliniken Regensburg Recruiting
Regensburg, Germany, 93053
Contact: Peter Hau, MD         
Principal Investigator: Peter Hau         
Spaarne Gasthuis - Vrije Universiteit Medisch Centrum Recruiting
Amsterdam, Netherlands
Principal Investigator: Myra van Linde         
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis Recruiting
Amsterdam, Netherlands
Principal Investigator: Dieta Brandsma, Dr         
Medisch Centrum Haaglanden - Westeinde Recruiting
Den Haag, Netherlands, 2501
Principal Investigator: Martin J.B. Taphoorn, Dr         
University Medical Center Groningen Recruiting
Groningen, Netherlands
Principal Investigator: Annemiek Walenkamp, Dr         
Radboud University Medical Center Nijmegen Recruiting
Nijmegen, Netherlands, 6525
Principal Investigator: Johanna Gijtenbeek, Dr         
Erasmus MC Recruiting
Rotterdam, Netherlands
Principal Investigator: Martin van den Bent, Dr         
Universitair Medisch Centrum - Academisch Ziekenhuis Recruiting
Utrecht, Netherlands, 3584
Principal Investigator: Filip De Vos         
Oslo University Hospital - Radiumhospitalet Recruiting
Oslo, Norway
Principal Investigator: Petter Brandal         
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia) Recruiting
Badalona, Spain
Principal Investigator: Carmen Balana         
Hospital Universitario 12 De Octubre Recruiting
Madrid, Spain, 28041
Principal Investigator: Juan Manuel Sepulveda, Dr         
Clinica Universidad de Navarra - Clinica Universitaria De Navarra Recruiting
Pamplona, Spain
Principal Investigator: Gallego Jaime         
University Hospital of Geneva Recruiting
Geneva, Switzerland
Contact: Anna Patrikidou, MD         
Principal Investigator: Anna Patrikidou         
Centre Hospitalier Universitaire Vaudois Recruiting
Lausanne, Switzerland
Contact: Andreas Hottinger, MD         
Principal Investigator: Andreas Hottinger         
Kantonsspital Recruiting
Saint Gallen, Switzerland
Principal Investigator: Thomas Hundsberger         
UniversitaetsSpital Recruiting
Zürich, Switzerland
Contact: Patrick Roth, MD         
Principal Investigator: Patrick Roth         
United Kingdom
NHS Lothian - Western General Hospital Recruiting
Edinburgh, United Kingdom, EH4 2XU
Contact: Sara C. Erridge, MD         
Principal Investigator: Sara C. Erridge, MD         
Guy's and St Thomas' NHS - Guy s and St Thomas' NHS - Guy's Hospital Recruiting
London, United Kingdom
Principal Investigator: Lucy Brazil, DR         
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital Recruiting
Sheffield, United Kingdom, S10 2SJ
Principal Investigator: Susan Clenton, DR         
Sponsors and Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Canadian Cancer Trials Group
Layout table for investigator information
Principal Investigator: Patrick Roth EORTC Study Coordinator

Layout table for additonal information
Responsible Party: European Organisation for Research and Treatment of Cancer - EORTC Identifier: NCT03345095     History of Changes
Other Study ID Numbers: EORTC-BTG-1709
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:
Phase III
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents